The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain
- PMID: 2007852
- PMCID: PMC2190803
- DOI: 10.1084/jem.173.4.1025
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain
Abstract
Using domain switch chimeric antibodies, we confirm the important role of CH2 in complement activation. In addition, we demonstrate that the structures responsible for the differential ability of human IgG1 and IgG4 to activate complement are located at the COOH-terminal part (from residue 292 to 340) of the CH2 domain. The amino acids in CH2 that might be involved in complement interaction are discussed. While CH3 contributes to efficient complement activation, CH3 from IgG2 and CH3 IgG3 are equally effective.
Similar articles
-
Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement.Mol Immunol. 1997 Oct;34(14):1019-29. doi: 10.1016/s0161-5890(97)00112-0. Mol Immunol. 1997. PMID: 9488053
-
Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement.J Biol Chem. 1994 Feb 4;269(5):3469-74. J Biol Chem. 1994. PMID: 8106388
-
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.Immunology. 1995 Oct;86(2):319-24. Immunology. 1995. PMID: 7490135 Free PMC article.
-
The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation.Transplantation. 2018 Jan;102(1S Suppl 1):S7-S13. doi: 10.1097/TP.0000000000001816. Transplantation. 2018. PMID: 29266057 Review.
-
The Immunobiology of Immunoglobulin G4 and Complement Activation Pathways in IgG4-Related Disease.Curr Top Microbiol Immunol. 2017;401:61-73. doi: 10.1007/82_2016_39. Curr Top Microbiol Immunol. 2017. PMID: 27726003 Review.
Cited by
-
Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections.Nat Commun. 2022 Jan 28;13(1):558. doi: 10.1038/s41467-021-27949-3. Nat Commun. 2022. PMID: 35091550 Free PMC article.
-
Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization.Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13206-10. doi: 10.1073/pnas.95.22.13206. Proc Natl Acad Sci U S A. 1998. PMID: 9789066 Free PMC article.
-
Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9. J Immunother. 2013. PMID: 23719241 Free PMC article.
-
Factors affecting IgG4-mediated complement activation.Front Immunol. 2023 Jan 26;14:1087532. doi: 10.3389/fimmu.2023.1087532. eCollection 2023. Front Immunol. 2023. PMID: 36776883 Free PMC article.
-
Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV+ Human Primary B-cells.Mol Cancer Ther. 2021 Sep;20(9):1592-1602. doi: 10.1158/1535-7163.MCT-21-0074. Epub 2021 Jun 22. Mol Cancer Ther. 2021. PMID: 34158342 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources